Verici DX has reported progress in its kidney transplant diagnostics portfolio and a positive first quarter trading update. The company's CEO, Sara Barrington, participated in a Q&A session, discussing the company's developments. Verici DX is also working on a product called Tutivia, which may potentially disrupt transplant monitoring with real-time RNA insights.